The development and use of the LHRH analogs further decreased the use of DES in the treatment of prostate cancer because LHRH offered similar efficacy to that of orchiectomy with less physical and psychological trauma, and LHRH analogs did not cause increased thromboembolic complications as was seen with DES. This evidence concerns the gene GNRH1 and prostate cancer.